The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis

OBJECTIVE: Long-acting β(2)-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) are burdened by the potential risk of inducing cardiovascular serious adverse events (SAEs) in COPD patients. Since the risk of combining a LABA with a LAMA could be greater, we have carried out a quantitativ...

Descripción completa

Detalles Bibliográficos
Autores principales: Rogliani, Paola, Matera, Maria Gabriella, Ora, Josuel, Cazzola, Mario, Calzetta, Luigino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723113/
https://www.ncbi.nlm.nih.gov/pubmed/29255354
http://dx.doi.org/10.2147/COPD.S146338

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723113/
https://www.ncbi.nlm.nih.gov/pubmed/29255354
http://dx.doi.org/10.2147/COPD.S146338

Ejemplares similares